Vasculitis syndromes: Inducing remission in ANCA-positive vasculitis: time to RAVE?
Watts
Richard A
RA
D000284:Administration, Oral; D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000188:drug therapy* / Q000503:physiopathology; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001379:Azathioprine / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007275:Injections, Intravenous; D008775:Methylprednisolone / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D011239:Prednisolone / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D000069283:Rituximab; D012720:Severity of Illness Index
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab; D003520:Cyclophosphamide; D011239:Prednisolone; D001379:Azathioprine; D008775:Methylprednisolone